{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:32:30Z","timestamp":1789842750606,"version":"4.0.1"},"reference-count":11,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.24-0036","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:20:59Z","timestamp":1738362059000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["A Case Report of Severe Thrombocytopenic Purpura during Neoadjuvant Pembrolizumab Administration for Triple-Negative Breast Cancer"],"prefix":"10.70352","volume":"11","author":[{"given":"Ryoko","family":"Semba","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Tohyama","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ushiyama","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-7048","authenticated-orcid":false,"given":"Fumi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6177-6315","authenticated-orcid":false,"given":"Sakiko","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-6875","authenticated-orcid":false,"given":"Kanako","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sandigursky S, Mor A. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Rheumatol Rep 2018; 20: 65.","DOI":"10.1007\/s11926-018-0770-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol 2023; 14: 1167975.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217\u201338.","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810\u201321.","DOI":"10.1056\/NEJMoa1910549"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 2019; 122: 72\u201390.","DOI":"10.1016\/j.ejca.2019.07.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Haddad TC, Zhao S, Li M, et al. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother 2022; 71: 1157\u201365.","DOI":"10.1007\/s00262-021-03068-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Omar NE, El-Fass KA, Abushouk AI, et al. Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review. Front Immunol 2020; 11: 1354.","DOI":"10.3389\/fimmu.2020.01354"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Zhuang J, Du J, Guo X, et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thorac Cancer 2020; 11: 799\u2013804.","DOI":"10.1111\/1759-7714.13281"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Javaid A, Bennett C, Rao A, et al. Rare immune-related adverse events (irAEs): approach to diagnosis and management. Pharmaceut Med 2024; 38: 25\u201338.","DOI":"10.1007\/s40290-023-00508-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Santa-Maria CA, O\u2019Donnell M, Nunes R, et al. Integrating immunotherapy in early-stage triple-negative breast cancer: practical evidence-based considerations. J Natl Compr Canc Netw 2022; 20: 738\u201344.","DOI":"10.6004\/jnccn.2022.7025"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020; 6: 865\u201371.","DOI":"10.1001\/jamaoncol.2020.0726"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.24-0036\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:20:23Z","timestamp":1738387223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.24-0036\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.24-0036","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.24-0036"}}